氯吡格雷抵抗与基因多态性研究进展  

Research progresses of clopidogrel resistance and gene polymorphism

作　　者：彭文星[1] 冯频频 石秀锦[2] 杜海燕[2] 仇琪[2] 林阳[2] 

机构地区：[1]首都医科大学化学生物与药学院临床药学系,100069 [2]首都医科大学附属北京安贞医院药事部,100029

出　　处：《中国医药》2016年第5期773-776,共4页China Medicine

基　　金：重大新药创制科技项目（2012ZX09303016）

摘　　要：氯吡格雷基因多态性可明显影响血小板活性.细胞色素2C19、三磷酸腺苷结合盒亚家族B成员1和对氧磷酶1等基因突变与氯吡格雷抵抗有一定的相关性,不同的基因型发生氯吡格雷抵抗的比例和心血管事件发生率有明显差异.根据临床基因型检测结果合理调整给药方案可以减少患者血小板高活性的比例和临床不良事件的发生率.合理应用基因检测手段对提高患者的临床疗效具有重要意义.Gene polymorphism of clopidogrel can significantly affect the platelet activity.Gene mutation of cytochrome 2C19,ATP-binding cassette sub-family B member 1 and paraoxonase 1 are associated with clopidogrel resistance.Incidences of clopidogrel resistance and cardiovascular events are significantly different in patients with different genotype.Adjusting the regimen reasonably according to the genetic testing result can reduce the proportion of patients with highly active platelets and the incidence of clinical adverse events.Reasonable application of genetic testing is significant to improve clinical effects.

关 键 词：氯吡格雷 基因型 基因检测 

分 类 号：R34[医药卫生—基础医学]